RESUMEN
Transmissible spongiform encephalopathies often are caused by peripheral uptake of infectious prions, and the peripheral nervous system is involved in prion spread to the brain. Although the cellular prion protein is subjected to fast axonal transport, the mechanism of intranerval transport of infectious prions is unclear. Here we administered prions intranervally to transgenic mice overexpressing the four-repeat human tau protein, which exhibit defective fast axonal transport. These mice showed unaltered neuroinvasion, suggesting that transport mechanisms distinct from fast axonal transport effect prion neuroinvasion along peripheral nerves. Surprisingly, scrapie-sick tau transgenic mice accumulated intraneuronal deposits of hyperphosphorylated tau protein. The coincidence of tau and prion pathology resembled Gerstmann-Sträussler-Scheinker syndrome. These findings identify tau pathology as a possible end stretch of prion-induced neurodegeneration.
Asunto(s)
Transporte Axonal , Neuronas/metabolismo , Enfermedades por Prión/fisiopatología , Priones/fisiología , Proteínas tau/metabolismo , Animales , Encéfalo/patología , Química Encefálica , Progresión de la Enfermedad , Ganglios Espinales/química , Enfermedad de Gerstmann-Straussler-Scheinker/patología , Enfermedad de Gerstmann-Straussler-Scheinker/fisiopatología , Enfermedad de Gerstmann-Straussler-Scheinker/transmisión , Humanos , Ratones , Ratones Transgénicos , Microscopía Fluorescente , Neuronas/patología , Nervios Periféricos/fisiopatología , Fosforilación , Proteínas PrPSc/patogenicidad , Enfermedades por Prión/patología , Enfermedades por Prión/transmisión , Priones/análisis , Priones/patogenicidad , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , Isoformas de Proteínas/ultraestructura , Bazo/química , Bazo/patología , Tasa de Supervivencia , Proteínas tau/genética , Proteínas tau/ultraestructuraRESUMEN
A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal V (in Germany marketed as Infectovac Flu). Children aged 6 months to 6 years received one or two doses. Adverse events were documented by parents/legal guardians in a questionnaire for four days after vaccination. The rates of adverse events were low: 14% of vaccine exposures were associated with systemic and 25% with local adverse events. Most symptoms were mild to moderate and resolved within a few days. Nearly 100% of parents/legal guardians would agree to have their child vaccinated again with Inflexal V. Vaccination with Inflexal V was safe, well tolerated and highly accepted by parents/legal guardians.
Asunto(s)
Vacunas contra la Influenza/efectos adversos , Vacunas contra la Influenza/inmunología , Vacunas de Virosoma/efectos adversos , Vacunas de Virosoma/inmunología , Niño , Preescolar , Alemania , Humanos , Lactante , Vigilancia de Productos Comercializados , Encuestas y CuestionariosRESUMEN
Since the introduction to the Swiss market in 1997, Crucell (former Berna Biotech Ltd.), has sold over 41 million doses worldwide of the virosomal adjuvanted influenza vaccine, Inflexal V. Since 1992, 29 company sponsored clinical studies investigating the efficacy and safety of Inflexal V have been completed in which 3920 subjects participated. During its decade on the market, Inflexal V has shown an excellent tolerability profile due to its biocompatibility and purity. The vaccine contains no thiomersal or formaldehyde and its purity is reflected in the low ovalbumin content. By mimicking natural infection, the vaccine is highly efficacious. Inflexal V is the only adjuvanted influenza vaccine licensed for all age groups and shows a good immunogenicity in both healthy and immunocompromised elderly, adults and children. This review presents and discusses the experience with Inflexal V during the past decade.
Asunto(s)
Vacunas contra la Influenza/uso terapéutico , Gripe Humana/prevención & control , Virosomas/uso terapéutico , Adyuvantes Inmunológicos , Adulto , Anciano , Preescolar , Humanos , Vacunas contra la Influenza/economía , Vacunas contra la Influenza/inmunología , Gripe Humana/economía , Vacunas de Virosoma/economía , Vacunas de Virosoma/inmunología , Vacunas de Virosoma/uso terapéutico , Virosomas/inmunologíaRESUMEN
BACKGROUND: Despite the established benefit of intramuscular (i.m.) influenza vaccination, new adjuvants and delivery methods for comparable or improved immunogenicity are being explored. Intradermal (i.d.) antigen administration is hypothesized to initiate an efficient immune response at reduced antigen doses similar to that observed after i.m. full dose vaccination. METHODS: In a randomized, partially blinded phase II study 224, healthy adults aged >or=18 to Asunto(s)
Vacunas contra la Influenza/inmunología
, Vacunas de Virosoma/inmunología
, Administración Cutánea
, Adolescente
, Adulto
, Femenino
, Humanos
, Vacunas contra la Influenza/administración & dosificación
, Vacunas contra la Influenza/efectos adversos
, Masculino
, Persona de Mediana Edad
, Seguridad
, Vacunación
, Vacunas de Virosoma/administración & dosificación
, Vacunas de Virosoma/efectos adversos
RESUMEN
Measles virus (MV) has shown promise as an oncolytic virus in the treatment of different tumor models for human B-cell lymphoma, multiple myeloma, ovarian cancer, and glioma. We have shown that, in a phase I clinical trial, MV vaccine induces tumor regression in cutaneous T-cell lymphoma (CTCL) patients. Here, we investigated in detail, the effect of recombinant MV (rMV) vaccine strain in CTCL cell cultures, and in vivo in established CTCL xenografts in nude mice. The susceptibility of three CTCL cell lines, originating from patients, to rMV was tested by determination of cell surface expression of MV receptors. All cell lines expressed the receptors CD150 and CD46 and were easily infected by rMV and induced complete cell lysis. The cytoreductive activity was apparent in cells forming aggregates, indicating a cell-to-cell spread of MV and cytolysis owing to virus infection. Intratumoral (i.t.) injection of rMV, expressing enhanced green fluorescent protein induced complete regression of large established human CTCL tumors in nude mice, whereas tumors with control treatment progressed exponentially. Immunohistochemical analysis of tumor biopsies, after i.t. treatment, for MV-NP protein complex demonstrated replication of MV within the tumors. The data demonstrate the potential of MV as a therapeutic agent against CTCL.
Asunto(s)
Vacunas contra el Cáncer/uso terapéutico , Linfoma Cutáneo de Células T/terapia , Vacuna Antisarampión/uso terapéutico , Virus del Sarampión , Viroterapia Oncolítica/métodos , Virus Oncolíticos , Animales , Antígenos CD/análisis , Línea Celular Tumoral , Humanos , Linfoma Cutáneo de Células T/química , Virus del Sarampión/genética , Virus del Sarampión/fisiología , Proteína Cofactora de Membrana/análisis , Ratones , Ratones Desnudos , Virus Oncolíticos/genética , Virus Oncolíticos/fisiología , Receptores de Superficie Celular/análisis , Miembro 1 de la Familia de Moléculas Señalizadoras de la Activación Linfocitaria , Activación Viral , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Some cutaneous T-cell lymphomas, (CTCLs) clonal T cells are deficient in interferon signaling, making them promising targets for viral oncolysis. We evaluated cytopathic effects of measles virus (MV) in CTCL. CTCL cell lines and infiltrating lymphocytes in CTCL expressed MV receptors CD150 and CD46. In a phase 1 dose escalation trial a total of 16 injections of live MV, Edmonston-Zagreb vaccine strain, were given intratumorally to 5 patients with CTCL. Patients had antimeasles-serum antibodies and were pretreated with interferon-alpha to prevent uncontrolled virus spread. The well-tolerated treatment with MV resulted in clinical responses. Evaluation of biopsies, before and at 11 days after injection, by immunohistochemistry and reverse transcriptase-polymerase chain reaction (RT-PCR) demonstrated local viral activity with positive staining for MV nucleoprotein (NP), an increase of the interferon gamma (IFN-gamma)/CD4 and IFN-gamma/CD8 mRNA ratios and a reduced CD4/CD8 ratio. All patients demonstrated an increased antimeasles antibody titer after therapy. The data demonstrate that CTCLs are promising targets for an MV-based oncolytic therapy.